cliquez-ici<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"GamaMabs Pharma, une soci\u00e9t\u00e9 de biotechnologie sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019anticorps th\u00e9rapeutiques optimis\u00e9s ciblant le r\u00e9cepteur de l\u2019Hormone Anti-M\u00fcll\u00e9rienne (AMHR2) pour le traitement du cancer, annonce aujourd’hui la pr\u00e9sentation de donn\u00e9es cliniques de l\u2019 \u00e9tude C101 de phase Ia\/Ib de son anticorps GM102 \u00e0 l\u2019occasion du congr\u00e8s annuel de l’American Society of Clinical Oncology (ASCO),…<\/p>\n","protected":false},"author":5,"featured_media":2395,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-2392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biodiscovery"],"acf":[],"yoast_head":"\n
GamaMabs Pharma pr\u00e9sente au congr\u00e8s ASCO 2018 des r\u00e9sultats de son premier essai clinique de GM102 dans les cancers gyn\u00e9cologiques de stade avanc\u00e9 - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GamaMabs Pharma pr\u00e9sente au congr\u00e8s ASCO 2018 des r\u00e9sultats de son premier essai clinique de GM102 dans les cancers gyn\u00e9cologiques de stade avanc\u00e9 - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"GamaMabs Pharma, une soci\u00e9t\u00e9 de biotechnologie sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019anticorps th\u00e9rapeutiques optimis\u00e9s ciblant le r\u00e9cepteur de l\u2019Hormone Anti-M\u00fcll\u00e9rienne (AMHR2) pour le traitement du cancer, annonce aujourd’hui la pr\u00e9sentation de donn\u00e9es cliniques de l\u2019 \u00e9tude C101 de phase Ia\/Ib de son anticorps GM102 \u00e0 l\u2019occasion du congr\u00e8s annuel de l’American Society of Clinical Oncology (ASCO),...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-22T13:45:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-09-28T14:04:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Stagiaire Communication\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Stagiaire Communication\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/\"},\"author\":{\"name\":\"Stagiaire Communication\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/c00e4b2e37dad5476a07678494c723e8\"},\"headline\":\"GamaMabs Pharma pr\u00e9sente au congr\u00e8s ASCO 2018 des r\u00e9sultats de son premier essai clinique de GM102 dans les cancers gyn\u00e9cologiques de stade avanc\u00e9\",\"datePublished\":\"2018-05-22T13:45:54+00:00\",\"dateModified\":\"2020-09-28T14:04:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/\"},\"wordCount\":111,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg\",\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/\",\"name\":\"GamaMabs Pharma pr\u00e9sente au congr\u00e8s ASCO 2018 des r\u00e9sultats de son premier essai clinique de GM102 dans les cancers gyn\u00e9cologiques de stade avanc\u00e9 - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg\",\"datePublished\":\"2018-05-22T13:45:54+00:00\",\"dateModified\":\"2020-09-28T14:04:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#primaryimage\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg\",\"width\":1024,\"height\":512},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GamaMabs Pharma pr\u00e9sente au congr\u00e8s ASCO 2018 des r\u00e9sultats de son premier essai clinique de GM102 dans les cancers gyn\u00e9cologiques de stade avanc\u00e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/c00e4b2e37dad5476a07678494c723e8\",\"name\":\"Stagiaire Communication\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b8fc49c2885cc8bd47fc12d37bdc253b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b8fc49c2885cc8bd47fc12d37bdc253b?s=96&d=mm&r=g\",\"caption\":\"Stagiaire Communication\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GamaMabs Pharma pr\u00e9sente au congr\u00e8s ASCO 2018 des r\u00e9sultats de son premier essai clinique de GM102 dans les cancers gyn\u00e9cologiques de stade avanc\u00e9 - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/","og_locale":"fr_FR","og_type":"article","og_title":"GamaMabs Pharma pr\u00e9sente au congr\u00e8s ASCO 2018 des r\u00e9sultats de son premier essai clinique de GM102 dans les cancers gyn\u00e9cologiques de stade avanc\u00e9 - ANDERA PARTNERS","og_description":"GamaMabs Pharma, une soci\u00e9t\u00e9 de biotechnologie sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019anticorps th\u00e9rapeutiques optimis\u00e9s ciblant le r\u00e9cepteur de l\u2019Hormone Anti-M\u00fcll\u00e9rienne (AMHR2) pour le traitement du cancer, annonce aujourd’hui la pr\u00e9sentation de donn\u00e9es cliniques de l\u2019 \u00e9tude C101 de phase Ia\/Ib de son anticorps GM102 \u00e0 l\u2019occasion du congr\u00e8s annuel de l’American Society of Clinical Oncology (ASCO),...","og_url":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2018-05-22T13:45:54+00:00","article_modified_time":"2020-09-28T14:04:17+00:00","og_image":[{"width":1024,"height":512,"url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg","type":"image\/jpeg"}],"author":"Stagiaire Communication","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Stagiaire Communication"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/"},"author":{"name":"Stagiaire Communication","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/c00e4b2e37dad5476a07678494c723e8"},"headline":"GamaMabs Pharma pr\u00e9sente au congr\u00e8s ASCO 2018 des r\u00e9sultats de son premier essai clinique de GM102 dans les cancers gyn\u00e9cologiques de stade avanc\u00e9","datePublished":"2018-05-22T13:45:54+00:00","dateModified":"2020-09-28T14:04:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/"},"wordCount":111,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg","articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/","url":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/","name":"GamaMabs Pharma pr\u00e9sente au congr\u00e8s ASCO 2018 des r\u00e9sultats de son premier essai clinique de GM102 dans les cancers gyn\u00e9cologiques de stade avanc\u00e9 - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#primaryimage"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg","datePublished":"2018-05-22T13:45:54+00:00","dateModified":"2020-09-28T14:04:17+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#primaryimage","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg","width":1024,"height":512},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/gamamabs-pharma-presente-au-congres-asco-2018-des-resultats-de-son-premier-essai-clinique-de-gm102-dans-les-cancers-gynecologiques-de-stade-avance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"GamaMabs Pharma pr\u00e9sente au congr\u00e8s ASCO 2018 des r\u00e9sultats de son premier essai clinique de GM102 dans les cancers gyn\u00e9cologiques de stade avanc\u00e9"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/c00e4b2e37dad5476a07678494c723e8","name":"Stagiaire Communication","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b8fc49c2885cc8bd47fc12d37bdc253b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b8fc49c2885cc8bd47fc12d37bdc253b?s=96&d=mm&r=g","caption":"Stagiaire Communication"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/2392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=2392"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/2392\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media\/2395"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=2392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=2392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/05\/GamaMabs-Logo-100.jpg\"){kind=logo}
GamaMabs Pharma, une soci\u00e9t\u00e9 de biotechnologie sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019anticorps th\u00e9rapeutiques optimis\u00e9s ciblant le r\u00e9cepteur de l\u2019Hormone Anti-M\u00fcll\u00e9rienne (AMHR2) pour le traitement du cancer, annonce aujourd’hui la pr\u00e9sentation de donn\u00e9es cliniques de l\u2019 \u00e9tude C101 de phase Ia\/Ib de son anticorps GM102 \u00e0 l\u2019occasion du congr\u00e8s annuel de l’American Society of Clinical Oncology (ASCO), le 4 juin \u00e0 Chicago, aux \u00c9tats-Unis.<\/p>\n